Merrell Dow Pharmaceuticals

Other

Merrell Pharmaceuticals, Inc.

The Dow Chemical Company

Ausio Pharmaceuticals, LLC

Jackson, Richard L.

Richard L Jackson

Alan D Cardin

Michael J Mullins

Simon J Mao

Keith M Robinson

Roger A Parker

John Kenneth Stacy

Ansel N John

George Ku

Andrew B Fox

Adam Guzik

David Conrath

The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochondrial target engagement biomarker to diagnose or assess the risk of developing Alzheimer's disease. Another aspect of the present invention includes the use of a pharmaceutically effective amount of S-equol to treat or prevent Alzheimer's disease in a subject diagnosed with or determined to be at risk of developing Alzheimer's disease.

Methods of diagnosing and treating Alzheimer's disease with S-equol

Embodiments of the present invention are directed to systems for powering and controlling lighting fixtures in office buildings, homes, industrial facilities, and similar structures using low-voltage direct-current ('DC') electricity. Some embodiments of the present invention are directed to systems for distributing DC power from a lighting controller to various LED luminaires. Embodiments include (a) a power source configured to provide electricity at approximately 48 volts DC; (b) an LED lighting fixture that includes a cool LED luminaire tuned toward the blue end of the visible light spectrum and a warm LED luminaire tuned toward the red end of the visible light spectrum; (c) a variable input control device for setting the color/temperature of the light emitted by the LED lighting fixture; and (d) a lighting controller comprising a watt meter, a capacitor bank, a cool LED controller, a warm LED controller, an input controller, a lighting computer; and (e) a site computer that communicates with the lighting controller via a building network to provide certain operational controls over the LED lighting fixture.

System for distributing low-voltage DC power to LED luminaires

An anhydrous crystalline form of S-equol has been discovered. Form I, the anhydrous crystalline form of S-equol has been isolated and characterized for the first time. As compared to other forms of S-equol, such as the known hydrate or other solvate forms, the anhydrous crystalline form of S-equol has improved properties.

[object Object]

A mechanism that allows for precise motion of the optics of an interferometer is comprised by two or more diaphragm flexures having high lateral stiffness, creating a superior performing Michelson interferometer. When coupled with precise precision control of a mirror surface and a reference laser, the above creates a superior performing Fourier transform spectrometer.

Mechanism for movement of a mirror in an interferometer, an interferometer incorporating the same and a fourier transform spectrometer incorporating the same

The oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are, pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.

Anti-herpes virus and cytomegalovirus polyurea oligomers

A a scoring tool which can be used to aid in removing wallpaper. The tool has a hand grip to which is connected a pair of cutting wheels. The wheels are mounted in the lower portion of the hand grip so the wheels diverge away from each other.

Scoring tool

Various peptides having affinity for sulfated polysaccharides such as heparin, dextran sulfate and Pentosan polysulfate are bound to resins and used in affinity chromatography to prepare anti-HIV sulfated polysaccharides.

Sulfated polysaccharide fractions having anti-HIV activity

A method of removing wall paper which includes the steps of dipping an absorbent fabric into water or a solution of aqueous wall paper remover. Allowing excess solution to drain from the fabric and then placing the fabric in direct contact with the wall paper. The fabric adheres to the wall merely through water cohesion. The fabric is allowed to remain on the wall paper for a period of time to allow the solution to soak into the paper. Once this occurs, the fabric is removed and the paper can be scraped off the wall.

Method of wallpaper removal

The oligomers of the present invention are polyamides having a number average molecular weight of &lt;10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.

Anti-herpes virus and cytomegalovirus polyamide oligomers

The preferred oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of &lt;10,000. These oligomers are water-soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geomentry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of AIDS and ARC.

Method of treating HIV infections with anti-viral formulations

Anti-HIV pharmaceutical formulations

The oligomers of the present invention are polyesters having a number average molecular weight of &lt;10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.

Anti-herpes virus and cytomegalovirus polyester oligomers

Anti-HIV oligomers

The oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of &lt;10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.

Anti-herpes virus and cytomegalovirus polycarbonate oligomers

The preferred oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of &lt;10,000. These oligomers are water-soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geomentry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of ARC.

Growing community of inventors

Cincinnati, OH, United States of America

Richard L Jackson